Harnessing Pharmacogenomics to Tackle Resistance to the “Nucleoside Reverse Trancripatse Inhibitor” Backbone of Highly Active Antiretroviral Therapy in Resource Limited Settings

Misaki Wayengera; Henry Kajumbula; Wilson Byarugaba

首页> 外文期刊>The open AIDS journal >Harnessing Pharmacogenomics to Tackle Resistance to the “Nucleoside Reverse Trancripatse Inhibitor” Backbone of Highly Active Antiretroviral Therapy in Resource Limited Settings

【24h】

Harnessing Pharmacogenomics to Tackle Resistance to the “Nucleoside Reverse Trancripatse Inhibitor” Backbone of Highly Active Antiretroviral Therapy in Resource Limited Settings

机译：在资源有限的环境中利用药物基因组学应对高活性抗逆转录病毒疗法对“核苷类逆转录转录酶抑制剂”骨架的耐药性

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundThe sustainable use of HAART within the sub-Saharan and other developing world settings faces the emerging challenge of drug resistance. Nucleoside reverse transcriptase inhibitors (NRTI) form the backbone of HAART and preserving their “antiviral efficacy” is thus critical to sustainable HAART use.

机译：背景技术在撒哈拉以南和其他发展中国家环境中可持续使用HAART面临着新出现的耐药性挑战。核苷逆转录酶抑制剂（NRTI）构成HAART的骨干，因此，保持其“抗病毒功效”对于可持续地使用HAART至关重要。

著录项

来源
《The open AIDS journal》 |2017年第1期|共4页
作者
Misaki Wayengera; Henry Kajumbula; Wilson Byarugaba;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类传染病;
关键词

相似文献

外文文献
中文文献
专利

1. Long‐term effectiveness of initiating non‐nucleoside reverse transcriptase inhibitor‐ versus ritonavir‐boosted protease inhibitor‐based antiretroviral therapy: implications for first‐line therapy choice in resource‐limited settings [J] . Viviane D Lima, Mark Hull, David McVea, Journal of the International Aids Society . 2016,第1期

机译：基于非核苷类逆转录酶抑制剂与利托那韦增强的蛋白酶抑制剂的抗逆转录病毒治疗的长期有效性：在资源有限的环境中对一线治疗选择的意义
2. Pharmacogenetics of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in resource-limited settings: Influence on antiretroviral therapy response and concomitant anti-tubercular, antimalarial and contraceptive treatments [J] . Russo Gianluca, Paganotti Giacomo Maria, Soeria-Atmadja Sandra, Infection, Genetics and Evolution: Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases . 2016,第Null期

机译：在资源有限的环境中非核苷类逆转录酶抑制剂（NNRTIs）的药理遗传学：对抗逆转录病毒疗法反应以及伴随的抗结核，抗疟疾和避孕疗法的影响
3. Evaluating the role of etravirine in the second-line antiretroviral therapy after failing an initial non-nucleoside reverse transcriptase inhibitor-based regimen in a resource-limited setting. [J] . Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Current HIV research . 2008,第5期

机译：在资源有限的情况下，基于初始非核苷类逆转录酶抑制剂的治疗方案失败后，评估依曲韦林在二线抗逆转录病毒治疗中的作用。
4. The Measurement of Nucleoside Reverse Transcriptase Inhibitor (NRTI) Antiretroviral Drugs by LC-MS/MS For Research Use Only. Not for Use in Diagnostic Procedures [C] . YunYun Zou, Michael Jarvis, Jeff Rivera American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2012

机译：LC-MS / MS仅测量核苷逆转录酶抑制剂（NRTI）抗逆转录病毒药物进行研究使用。不用于诊断过程
5. A study of CD4-stratified timing of antiretroviral therapy among patients receiving integrated tuberculosis and HIV treatment in a highly resource-limited setting. [D] . Patel, Monita R. 2013

机译：在资源有限的情况下，对接受结核病和艾滋病毒综合治疗的患者进行CD4分层抗逆转录病毒治疗时机的研究。
6. Harnessing Pharmacogenomics to Tackle Resistance to the Nucleoside Reverse Trancripatse Inhibitor Backbone of Highly Active Antiretroviral Therapy in Resource Limited Settings [O] . Misaki Wayengera, Henry Kajumbula, Wilson Byarugaba 2008

机译：在资源有限的环境中利用药物基因组学应对高活性抗逆转录病毒疗法的核苷逆转录酶抑制剂骨架的耐药性
7. Harnessing Pharmacogenomics to Tackle Resistance to the “Nucleoside Reverse Trancripatse Inhibitor” Backbone of Highly Active Antiretroviral Therapy in Resource Limited Settings [O] . Wayengera, Misaki, Kajumbula, Henry, Byarugaba, Wilson 2008

机译：在资源有限的环境中利用药物基因组学解决对高效抗逆转录病毒疗法的“核苷逆转录酶抑制剂”骨架的耐药性

Harnessing Pharmacogenomics to Tackle Resistance to the “Nucleoside Reverse Trancripatse Inhibitor” Backbone of Highly Active Antiretroviral Therapy in Resource Limited Settings

摘要

著录项

相似文献

相关主题

期刊订阅